| Candidate ID: | R0372 |
| Source ID: | DB01017 |
| Source Type: | approved; investigational |
| Compound Type: |
small molecule
|
| Compound Name: |
Minocycline
|
| Synonyms: |
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; Minocyclin; Minocycline; Minomycin
|
| Molecular Formula: |
C23H27N3O7
|
| SMILES: |
[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
|
| Structure: |
|
| DrugBank Description: |
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Minocycline was granted FDA approval on 30 June 1971.
|
| CAS Number: |
10118-90-8
|
| Molecular Weight: |
457.4764
|
| DrugBank Indication: |
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, _Mycoplasma pneumoniae_, _Chlamydia trachomatis_, _Chlamydophila psittaci_, _Chlamydia trachomatis_, _Ureaplasma urealyticum_, _Borrelia recurrentis_, _Haemophilus ducreyi_, _Yersinia pestis_, _Francisella tularensis_, _Vibrio cholerae_, _Campylobacter fetus_, _Brucella_ species, _Bartonella bacilliformis_, _Klebsiella granulomatis_, _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, _Haemophilus influenzae_, and _Kelbsiella_ species.
|
| DrugBank Pharmacology: |
Minocycline is a tetracycline antibiotic that binds to the bacterial 30S ribosomal subunit and interferes with protein synthesis. It is generally given 2-4 times daily, so the duration of action is short. Intravenous minocycline should not exceed 400mg in 24 hours. Patients should be counselled regarding the risks related to tooth and bone development, pseudomembranous colitis, central nervous system side effects, and pseudotumor cerebri.
|
| DrugBank MoA: |
Tetracyclines enter bacterial cells through OmpF and OmpC porins by coordinating with cations like magnesium. This allows tetracyclines into the periplasm where they dissociate, allowing the lipophilic tetracycline to diffuse into the bacterial cytoplasm. Tetracyclines prevent aminoacyl-tRNA from binding to the 30S ribosome, inhibiting protein synthesis.
|
| Targets: |
30S ribosomal protein S9 inhibitor; 30S ribosomal protein S4 inhibitor; 16S ribosomal RNA inhibitor; Interleukin-1 beta modulator; Arachidonate 5-lipoxygenase inhibitor; Matrix metalloproteinase-9 inhibitor; Vascular endothelial growth factor A inhibitor; Caspase-1 negative modulator; Caspase-3 negative modulator; Cytochrome c negative modulator; Mitogen-activated Protein Kinases inhibitor; Nitric oxide synthase, inducible inhibitor
|
| Inclusion Criteria: |
Target associated
|
